Protagonist Begin Period Cash Flow vs Capital Expenditures Analysis

PTGX Stock  USD 43.17  3.33  7.16%   
Protagonist Therapeutics financial indicator trend analysis is much more than just breaking down Protagonist Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protagonist Therapeutics is a good investment. Please check the relationship between Protagonist Therapeutics Begin Period Cash Flow and its Capital Expenditures accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Begin Period Cash Flow vs Capital Expenditures

Begin Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protagonist Therapeutics Begin Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have strong relationship.
The correlation between Protagonist Therapeutics' Begin Period Cash Flow and Capital Expenditures is 0.76. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Protagonist Therapeutics, assuming nothing else is changed. The correlation between historical values of Protagonist Therapeutics' Begin Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Protagonist Therapeutics are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Begin Period Cash Flow i.e., Protagonist Therapeutics' Begin Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.76
Relationship DirectionPositive 
Relationship StrengthSignificant

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Protagonist Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Protagonist Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most indicators from Protagonist Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protagonist Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Enterprise Value is likely to rise to about 1.2 B in 2024, whereas Selling General Administrative is likely to drop slightly above 18 M in 2024.
 2021 2022 2023 2024 (projected)
Interest Income443K4.1M12.9M13.6M
Net Interest Income443K4.1M12.9M13.6M

Protagonist Therapeutics fundamental ratios Correlations

0.810.83-0.25-0.040.990.72-0.87-0.850.390.870.520.251.00.620.940.960.23-0.030.460.420.3-0.80.871.00.1
0.810.61-0.36-0.490.870.45-0.75-0.690.290.730.32-0.190.820.260.780.780.330.080.250.220.37-0.570.690.820.09
0.830.61-0.450.20.830.77-0.69-0.620.550.710.710.540.820.510.730.790.210.110.180.110.29-0.690.720.820.21
-0.25-0.36-0.45-0.16-0.35-0.52-0.090.0-0.570.09-0.58-0.26-0.240.43-0.24-0.32-0.56-0.670.690.71-0.590.22-0.39-0.24-0.01
-0.04-0.490.2-0.16-0.120.490.280.050.19-0.220.240.81-0.070.21-0.010.05-0.050.31-0.12-0.15-0.03-0.240.22-0.050.08
0.990.870.83-0.35-0.120.7-0.84-0.810.440.830.560.20.990.520.910.960.280.020.360.320.34-0.770.840.980.03
0.720.450.77-0.520.490.7-0.41-0.590.410.460.540.550.70.390.680.830.260.440.080.040.32-0.750.860.710.19
-0.87-0.75-0.69-0.090.28-0.84-0.410.91-0.26-1.0-0.3-0.07-0.87-0.72-0.86-0.74-0.230.39-0.73-0.69-0.280.71-0.66-0.87-0.19
-0.85-0.69-0.620.00.05-0.81-0.590.91-0.25-0.92-0.28-0.14-0.86-0.7-0.92-0.8-0.410.24-0.72-0.69-0.450.84-0.85-0.86-0.17
0.390.290.55-0.570.190.440.41-0.26-0.250.260.380.640.390.190.40.370.380.35-0.2-0.230.42-0.620.320.390.08
0.870.730.710.09-0.220.830.46-1.0-0.920.260.310.120.870.760.860.760.22-0.370.740.70.27-0.740.690.870.2
0.520.320.71-0.580.240.560.54-0.3-0.280.380.310.360.510.090.390.50.37-0.06-0.14-0.160.42-0.250.440.49-0.36
0.25-0.190.54-0.260.810.20.55-0.07-0.140.640.120.360.230.450.250.27-0.020.28-0.04-0.090.03-0.540.310.240.17
1.00.820.82-0.24-0.070.990.7-0.87-0.860.390.870.510.230.610.940.960.24-0.040.460.420.3-0.790.861.00.1
0.620.260.510.430.210.520.39-0.72-0.70.190.760.090.450.610.590.56-0.24-0.380.840.8-0.2-0.70.470.620.09
0.940.780.73-0.24-0.010.910.68-0.86-0.920.40.860.390.250.940.590.880.43-0.020.50.450.48-0.860.920.950.24
0.960.780.79-0.320.050.960.83-0.74-0.80.370.760.50.270.960.560.880.180.140.370.330.24-0.80.90.960.05
0.230.330.21-0.56-0.050.280.26-0.23-0.410.380.220.37-0.020.24-0.240.430.180.07-0.13-0.121.0-0.320.450.220.08
-0.030.080.11-0.670.310.020.440.390.240.35-0.37-0.060.28-0.04-0.38-0.020.140.07-0.66-0.690.08-0.160.21-0.030.33
0.460.250.180.69-0.120.360.08-0.73-0.72-0.20.74-0.14-0.040.460.840.50.37-0.13-0.660.99-0.12-0.450.340.470.08
0.420.220.110.71-0.150.320.04-0.69-0.69-0.230.7-0.16-0.090.420.80.450.33-0.12-0.690.99-0.12-0.410.290.43-0.01
0.30.370.29-0.59-0.030.340.32-0.28-0.450.420.270.420.030.3-0.20.480.241.00.08-0.12-0.12-0.370.50.290.09
-0.8-0.57-0.690.22-0.24-0.77-0.750.710.84-0.62-0.74-0.25-0.54-0.79-0.7-0.86-0.8-0.32-0.16-0.45-0.41-0.37-0.83-0.8-0.24
0.870.690.72-0.390.220.840.86-0.66-0.850.320.690.440.310.860.470.920.90.450.210.340.290.5-0.830.870.21
1.00.820.82-0.24-0.050.980.71-0.87-0.860.390.870.490.241.00.620.950.960.22-0.030.470.430.29-0.80.870.12
0.10.090.21-0.010.080.030.19-0.19-0.170.080.2-0.360.170.10.090.240.050.080.330.08-0.010.09-0.240.210.12
Click cells to compare fundamentals

Protagonist Therapeutics Account Relationship Matchups

Protagonist Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets154.9M324.5M347.7M247.9M358.0M204.1M
Other Current Liab(10.2M)21.2M38.6M25.0M19.4M13.5M
Total Current Liabilities35.4M40.2M44.0M31.2M21.3M27.7M
Total Stockholder Equity(217.7M)(283.8M)(409.4M)(536.8M)336.7M353.5M
Net Tangible Assets80.0M279.6M300.0M215.6M247.9M141.3M
Property Plant And Equipment Net7.7M6.4M6.7M4.6M2.1M3.4M
Net Debt(16.0M)(111.4M)(117.8M)(122.1M)(185.6M)(176.3M)
Retained Earnings(217.7M)(283.8M)(409.4M)(536.8M)(615.7M)(584.9M)
Accounts Payable2.8M3.1M1.6M3.6M772K733.4K
Cash33.0M117.4M123.7M125.7M186.7M196.1M
Non Current Assets Total9.6M8.9M7.0M10.6M2.4M2.3M
Other Assets450K1.1M1.9M225K258.8K245.8K
Cash And Short Term Investments133.0M307.8M326.9M237.4M341.6M191.4M
Net Receivables6.8M3.5M4.4M52K10.3M10.8M
Common Stock Shares Outstanding25.9M34.4M46.3M49.0M56.8M29.8M
Short Term Investments100.0M188.5M203.2M111.6M154.9M99.8M
Liabilities And Stockholders Equity(142.7M)(238.9M)(361.7M)247.9M358.0M375.8M
Non Current Liabilities Total39.5M4.6M3.7M784.7M221K210.0K
Inventory4.8M4.0M8.5M(94K)(10.3M)(9.8M)
Other Current Assets744K311K975K42K14.0M14.7M
Other Stockholder Equity221K(28K)299K359K952.5M1.0B
Total Liab75.0M44.9M47.7M784.7M21.3M20.2M
Property Plant And Equipment Gross7.7M6.4M11.0M9.9M8.4M5.1M
Total Current Assets145.3M315.6M340.7M237.4M355.6M196.9M
Accumulated Other Comprehensive Income(221K)28K(299K)(359K)(105K)(110.3K)
Property Plant Equipment7.7M1.5M6.7M1.6M1.8M2.5M
Capital Surpluse297.8M563.4M709.7M752.7M865.6M908.9M
Retained Earnings Total Equity(217.7M)(283.8M)(409.4M)(536.8M)(483.1M)(458.9M)
Current Deferred Revenue41.5M14.5M1.6M69K3K2.9K
Net Invested Capital89.8M279.6M300.0M215.6M336.7M228.6M
Net Working Capital109.9M275.4M296.7M211.9M334.3M227.5M
Short Term Debt1.3M1.5M2.2M2.5M1.1M1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.